Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 15/20 | 0.57 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.57 |
| ▸ | AURKA | O14965 | 2/20 | 0.57 |
| ▸ | JAK2 | O60674 | 1/20 | 0.56 |
| ▸ | IGF1R | P08069 | 1/20 | 0.56 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.56 |
| ▸ | CCNK | O75909 | 2/20 | 0.48 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.48 |
| ▸ | CDK2 | P24941 | 2/20 | 0.48 |
| ▸ | CCND3 | P30281 | 2/20 | 0.48 |
| ▸ | CDK9 | P50750 | 2/20 | 0.48 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.48 |
| ▸ | BRD4 | O60885 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25549625 | 0.85 | AXL (0.67) | AXLAURKBAURKAJAK2IGF1R | |
| SCHEMBL25549741 | 0.81 | AXL (0.84) | AXLAURKBAURKAJAK2IGF1R | |
| SCHEMBL13641247 | 0.81 | AXL (0.84) | AXLAURKBAURKAJAK2IGF1R | |
| SCHEMBL22909223 | 0.79 | AXL (0.68) | AXLAURKBAURKAJAK2IGF1R | |
| SCHEMBL25550379 | 0.78 | AXL (0.67) | AXLAURKBAURKAJAK2IGF1R | |
| SCHEMBL270946 | 0.75 | AXL (0.80) | AXLAURKBJAK2IGF1RALK | |
| SCHEMBL22872058 | 0.74 | AXL (0.71) | AXLAURKBAURKAJAK2IGF1R | |
| SCHEMBL24073135 | 0.74 | AXL (0.70) | AXLAURKBAURKAJAK2IGF1R | |
| SCHEMBL25550078 | 0.73 | AXL (0.83) | AXLAURKBAURKAJAK2IGF1R | |
| SCHEMBL25550361 | 0.73 | AXL (0.70) | AXLAURKBAURKAJAK2IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230165857-A1 | AXL KINASE INHIBITORS AND USE OF THE SAME | SUMITOMO PHARMA ONCOLOGY, INC. | 2023-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230165857-A1 | AXL KINASE INHIBITORS AND USE OF THE SAME | AXL, FLT3, TEC | AXL 1/4885AURKB 164/4885AURKA 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.